Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SRDX

Surmodics (SRDX) Stock Price, News & Analysis

Surmodics logo

About Surmodics Stock (NASDAQ:SRDX)

Key Stats

Today's Range
$41.85
$43.00
50-Day Range
$26.42
$42.98
52-Week Range
$25.87
$43.00
Volume
5.34 million shs
Average Volume
269,318 shs
Market Capitalization
$614.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Surmodics, Inc. (NASDAQ: SRDX) is a medical technology company specializing in surface modification and drug-eluting coating technologies for medical devices and in vitro diagnostic applications. The company’s core expertise lies in polymer-based solutions that enhance device performance, including hydrophilic coatings to improve catheter lubricity and drug-delivery coatings for cardiovascular and peripheral vascular stents. Surmodics also offers proprietary diagnostic assay platforms and automation solutions for clinical laboratories.

Surmodics’ product portfolio is organized around two main segments: medical device and in vitro diagnostics. In the medical device segment, the company provides therapeutic delivery coatings, surface modifiers, and adhesive technologies for customers developing implants, guide wires, and catheters. On the diagnostics side, Surmodics supplies reagents, assay calibrators, and control materials, as well as instrumentation used in immunoassay and molecular diagnostic workflows.

Founded in Eden Prairie, Minnesota, in 1986, Surmodics has expanded its operations to serve a global client base across North America, Europe, and Asia. The company’s research and development efforts focus on advancing biocompatible polymers and next-generation delivery systems, while its manufacturing facilities adhere to international quality standards. Surmodics collaborates with a diverse set of medical device OEMs, contract manufacturers, and diagnostic companies to bring customized surface and assay solutions to market.

Surmodics is led by President and Chief Executive Officer Richard Carlin, who has overseen strategic partnerships and product launches since taking the helm in 2016. The company maintains a governance structure aimed at innovation and regulatory compliance, with a board comprised of directors experienced in medical technology, life sciences, and global business operations. Through ongoing investment in R&D and customer-driven development, Surmodics seeks to address clinical challenges and improve patient outcomes worldwide.

AI Generated. May Contain Errors.

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRDX Stock News Headlines

Endologix purchases thrombectomy system from Surmodics
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.tc pixel
SurModics Completes Merger, Ends Credit Agreement
See More Headlines

SRDX Stock Analysis - Frequently Asked Questions

Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings data on Friday, August, 8th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.27. The business had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics had a negative trailing twelve-month return on equity of 2.99% and a negative net margin of 14.59%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/08/2025
Today
8/02/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:SRDX
CIK
924717
Employees
450
Year Founded
1979

Profitability

EPS (Trailing Twelve Months)
($1.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
214.90
P/E Growth
N/A
Net Income
-$11.54 million
Net Margins
-14.59%
Pretax Margin
-12.16%
Return on Equity
-2.99%
Return on Assets
-1.99%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
3.91
Quick Ratio
3.10

Sales & Book Value

Annual Sales
$120.80 million
Price / Sales
5.09
Cash Flow
$0.49 per share
Price / Cash Flow
87.04
Book Value
$8.33 per share
Price / Book
5.16

Miscellaneous

Outstanding Shares
14,298,000
Free Float
13,025,000
Market Cap
$614.53 million
Optionable
Optionable
Beta
1.30

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SRDX) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners